open access

Vol 60, No 6 (2009)
Original papers
Published online: 2009-12-30
Submitted: 2013-02-15
Get Citation

Homocysteine, folate, and cobalamin levels in hyperthyroid women before and after treatment

Anna Orzechowska-Pawilojc, Małgorzata Siekierska-Hellmann, Anhelli Syrenicz, Krzysztof Sworczak
Endokrynologia Polska 2009;60(6):443-448.

open access

Vol 60, No 6 (2009)
Original papers
Published online: 2009-12-30
Submitted: 2013-02-15

Abstract


Introduction: Hyperhomocysteinaemia is an independent risk factor for premature atherosclerotic vascular disease and venous thrombosis. Hypothyroidism is associated with mild hyperhomocysteinaemia. The aim of the present study was to assess plasma total homocysteine (tHcy) and its determinants (folate, cobalamin) in hyperthyroid patients before and after treatment.
Material and methods: Thirty hyperthyroid and thirty healthy premenopausal women were studied. The hyperthyroid patients were investigated in the untreated state and again after restoration of euthyroidism. The levels of homocysteine, folate, cobalamin, and thyroid stimulating hormone (TSH), free thyroxine (fT4), free triiodothyronine (fT3), and renal function were measured before and after treatment.
Results: In hyperthyroidism, tHcy was lower than in the control group. The serum level of folate was higher and serum cobalamin was lower in the hyperthyroid state. Following antithyroid drug therapy, tHcy significantly increased and folate decreased. The level of cobalamin remained unchanged. Univariate analysis in the hyperthyroid group indicated that tHcy significantly negatively correlated only with fT3.
Conclusions: Lower homocysteine levels in hyperthyroid state can be explained by the influence of thyroid hormone. High level of folate is only partially responsible for these changes.

Abstract


Introduction: Hyperhomocysteinaemia is an independent risk factor for premature atherosclerotic vascular disease and venous thrombosis. Hypothyroidism is associated with mild hyperhomocysteinaemia. The aim of the present study was to assess plasma total homocysteine (tHcy) and its determinants (folate, cobalamin) in hyperthyroid patients before and after treatment.
Material and methods: Thirty hyperthyroid and thirty healthy premenopausal women were studied. The hyperthyroid patients were investigated in the untreated state and again after restoration of euthyroidism. The levels of homocysteine, folate, cobalamin, and thyroid stimulating hormone (TSH), free thyroxine (fT4), free triiodothyronine (fT3), and renal function were measured before and after treatment.
Results: In hyperthyroidism, tHcy was lower than in the control group. The serum level of folate was higher and serum cobalamin was lower in the hyperthyroid state. Following antithyroid drug therapy, tHcy significantly increased and folate decreased. The level of cobalamin remained unchanged. Univariate analysis in the hyperthyroid group indicated that tHcy significantly negatively correlated only with fT3.
Conclusions: Lower homocysteine levels in hyperthyroid state can be explained by the influence of thyroid hormone. High level of folate is only partially responsible for these changes.
Get Citation

Keywords

homocysteine; cobalamin; folate; hyperthyroidism

About this article
Title

Homocysteine, folate, and cobalamin levels in hyperthyroid women before and after treatment

Journal

Endokrynologia Polska

Issue

Vol 60, No 6 (2009)

Pages

443-448

Published online

2009-12-30

Bibliographic record

Endokrynologia Polska 2009;60(6):443-448.

Keywords

homocysteine
cobalamin
folate
hyperthyroidism

Authors

Anna Orzechowska-Pawilojc
Małgorzata Siekierska-Hellmann
Anhelli Syrenicz
Krzysztof Sworczak

Important: This website uses cookies.tanya dokter More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via MedicaWydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl